万孚生物 (300482.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

49.4x

Market Cap

CNY 7.49B

MomentumView details →

1D Return

−8.05%

YTD Return

−15.24%

RSI (14)

47.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

49.4x

Market Cap

CNY 7.49B

RSI (14)

47.6

MomentumView details →

1D Return

−8.05%

YTD Return

−15.24%

ProfitabilityView details →

Gross Margin

54.77%

Net Margin

−8.98%

EBITDA Margin

8.17%

ROE (TTM)

−3.04%

ROA (TTM)

−2.49%

Asset Turnover

0.28x

GrowthView details →

Revenue YoY

−37.81%

EPS YoY

—

FCF YoY

+385.00%

Revenue CAGR 3Y

−28.38%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.08

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−1.08%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.22x

Quick Ratio

2.97x

Div Yield

1.31%

Div Rate

CNY 0.22

Div Growth 1Y

−45.00%

Financials snapshotView financials →

Revenue (TTM)

1.87B

Net Income (TTM)

−167.76M

Op. CF (TTM)

830.00M

Latest newsMore news →

Wondfo Biotech received 7 chemiluminescence medical device registration certificates from the Guangdong Provincial Drug Administration, covering test kits for homocysteine, insulin, glycated hemoglobin controls and calibrators, laminin, procollagen III N-terminal peptide, and collagen IV, for liver disease, diabetes, and cardiovascular disease testing.12d ago

Wondfo Biotech announced its first-half 2026 results: revenue of 1.039 billion yuan, down 16.63% year-on-year; net profit attributable to shareholders of 123 million yuan, down 35.24% year-on-year.12d ago

Similar companies

亿道信息001314.SZ 精研科技300709.SZ 五洲医疗301234.SZ 仁和药业000650.SZ 天宇股份300702.SZ 中天火箭003009.SZ Find similar companies →

Latest newsMore news →

Wondfo Biotech received 7 chemiluminescence medical device registration certificates from the Guangdong Provincial Drug Administration, covering test kits for homocysteine, insulin, glycated hemoglobin controls and calibrators, laminin, procollagen III N-terminal peptide, and collagen IV, for liver disease, diabetes, and cardiovascular disease testing.12d ago Wondfo Biotech announced its first-half 2026 results: revenue of 1.039 billion yuan, down 16.63% year-on-year; net profit attributable to shareholders of 123 million yuan, down 35.24% year-on-year.12d ago